Featured Story | By Annalee Armstrong It’s the rare triple down: Bristol Myers Squibb is once again revising a massive research collaboration with immunotherapy drug discovery biotech Immatics. BMS is adding new deal with $60 million upfront and $700 million down the line for at least two new programs, plus expanding its prior arrangement. read more |
| |
|---|
|
Top Stories By Annalee Armstrong It's not every day that a biotech's scientific co-founder is arrested on murder-for-hire charges. But the aftermath of that arrest is just what Enochian Biosciences' CEO faces now—and he's fighting back against short-sellers and their "thinly veiled attempt to smear" the company. read more By Gabrielle Masson Michael Severino, M.D., is leaving AbbVie and big pharma behind—but that’s not the end of the story. The leader is already entering his next chapter at Tessera Therapeutics, stepping into the world of biotech as CEO of the gene writing and rewriting company. read more By Max Bayer As the protein degradation field continues to grow, Merck KGaA has decided it needs more than one baton in the metaphorical clinical relay race, inking a $554 million deal with Austrian biotech Proxygen. read more By Annalee Armstrong The last time Samantha Truex was CEO of a biotech, she did something rare: She admitted defeat. Now, Truex is back at the helm of Upstream Bio, a new inflammatory disease biotech that has been quietly building over the past few months and is ready to reveal today with a whopping $200 million in financing. read more By Nick Paul Taylor Roche is joining AstraZeneca, Bayer, Merck KGaA and more in a synthetic lethality race, paying Repare Therapeutics $125 million upfront for an ATR inhibitor with monotherapy and combination applications in indications such as ovarian cancer. read more By Nick Paul Taylor Nordic Nanovector has responded to the glacial pace of enrollment in its phase 2b follicular lymphoma clinical trial. After failing to enroll any patients in May, the Norwegian biotech has decided to conduct a “comprehensive review” of all aspects of the flatlining study. read more By Angus Liu In Alzheimer’s disease, the loss of neuronal nexus called synapse contributes to the progressive cognitive decline. Now, scientists at Yale University found that an experimental drug originally developed by Bristol Myers Squibb for schizophrenia repair that damage in mice. read more By Gabrielle Masson After resisting as long as it could, small oncology biotech Atreca has finally succumbed to the layoff surge pulling in other fellow biotechs and plans to cull a quarter of its workforce. read more By Max Bayer Centessa Pharmaceuticals’ is taking the ax to its sole phase 3 program after evidence of tolerability issues in an open-label trial spurred questions about the market potential. read more By Annalee Armstrong Bezyl is teaming up with contract research organization Thread to provide clinical trial patients with access to the digital mental health company’s app and support systems. read more By Annalee Armstrong Oncology trial starts reached record levels in 2021—particularly in rare indications—as disruptions in cancer care brought on by the COVID-19 pandemic began to ease, according to the IQVIA Institute for Human Data Science. read more By Angus Liu In Alzheimer’s disease, the loss of neuronal nexus called synapse contributes to the progressive cognitive decline. Now, scientists at Yale University found that an experimental drug originally developed by Bristol Myers Squibb for schizophrenia repair that damage in mice. read more By Joseph Keenan Sana Biotechnology, which raised a whopping $588 million in its initial public offering last year, has inked a deal for new manufacturing space. The move up the West Coast will save the company $100 million over three years. read more Resources Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored by: Catalent In this executive summary, we describe the benefits of controlled release, look at how to determine whether a drug is suitable for controlled release, review the application of PBPK modelling in controlled release formulation development and discuss how modified release products can be developed to deliver optimal patient outcomes. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? | 
